Mantle Cell Lymphoma · Pirtobrutinib monotherapy continuous (BRUIN MCL schedule, post-cBTKi)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | REG-PIRTOBRUTINIB-MCL |
| ID | IND-MCL-3L-PIRTOBRUTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Co-Lead sign-off. Standard-track 3L+ option for r/r MCL post-cBTKi resistance. Often used as bridge to brexu-cel CAR-T when CAR-T accessible. UA access barrier dominant.
Used By
Algorithms
ALGO-MCL-2L- ALGO-MCL-2LALGO-MCL-3L- ALGO-MCL-3L
Indication
IND-MCL-3L-LISOCEL- IND-MCL-3L-LISOCEL